Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17394554 | 0.83 | TSHR (0.33) | LTA4H | |
| SCHEMBL8540552 | 0.78 | LMNA (0.47) | LTA4HMMP1SCN9ALMNAMAPT | |
| SCHEMBL7759460 | 0.77 | LTA4H (0.57) | LTA4H | |
| SCHEMBL28129946 | 0.76 | LTA4H (0.55) | LTA4H | |
| SCHEMBL3256252 | 0.74 | ALDH1A1 (0.61) | LTA4HMAPT | |
| SCHEMBL22061918 | 0.71 | LMNA (0.44) | LTA4HMMP1SCN9ALMNAMAPT | |
| SCHEMBL28396334 | 0.70 | KDM4C (0.46) | LTA4HMMP1SCN9ALMNA | |
| SCHEMBL1680381 | 0.69 | LTA4H (0.67) | LTA4HLMNAMAPTMMP13 | |
| SCHEMBL3256253 | 0.67 | PARP10 (0.68) | MAPT | |
| Ammonia Solution, Strong SCHEMBL3454484 | 0.67 | LTA4H (0.63) | LTA4HLMNAMAPTMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12117439-B2 | Compositions and methods for using fixed biological samples | 10X GENOMICS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240125772-A1 | COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLES IN PARTITION-BASED ASSAYS | 10X GENOMICS, INC. | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12117439-B2 | Compositions and methods for using fixed biological samples | FBL, ALKBH1, NOP2 | LTA4H 1783/4885MMP1 1084/4885SCN9A 4279/4885 |
| US-20240125772-A1 | COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLES IN PARTITION-BASED ASSAYS | FBL, DIS3, ALKBH1 | LTA4H 1861/4885MMP1 1461/4885SCN9A 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.